Menstrual Cycle Physiology
The Normal Menstrual Cycle
| Phase | Days | Key Hormones | Ovarian Event | Endometrium |
|---|---|---|---|---|
| Menstruation | 1–5 | All low; prostaglandin release | Corpus luteum regression | Shedding |
| Proliferative (Follicular) | 1–14 | FSH ↑ → follicle growth → oestrogen ↑ | Dominant follicle selection | Proliferation (oestrogen-driven) |
| Ovulation | ~14 | LH surge (mid-cycle peak) | Follicle rupture; oocyte release | Peak proliferation |
| Secretory (Luteal) | 14–28 | Progesterone ↑↑ (corpus luteum), oestrogen moderate | Corpus luteum formation | Secretory transformation, decidualisation if pregnant |
Clinical Pearl
The luteal phase is fixed at approximately 14 days. Cycle length variation occurs in the follicular phase. A woman with a 35-day cycle ovulates around day 21, not day 14.
Normal Menstruation Parameters
Cycle Length
28 ± 7 days
Normal: 21–35 days
Duration
2–7 days
Median 5 days
Blood Loss
< 80 mL
Average 35–40 mL per cycle
Menorrhagia (Heavy Menstrual Bleeding)
Definition & NICE Assessment
NICE Definition (NG88, 2018)
HMB = excessive menstrual blood loss that interferes with physical, social, emotional, and/or material quality of life. Objective threshold >80 mL/cycle; in practice assessed by impact on quality of life.
| Assessment Tool | Details |
|---|---|
| PBAC (Pictorial Bleeding Assessment Chart) | Score lightly soaked pad/tampon = 1, moderately soaked = 5, saturated = 20; clots <1cm = 1, >1cm = 5. Score >100 correlates with blood loss >80 mL |
| Impact questionnaire | Ask about flooding, passing clots, changing protection at night, interference with daily activities, anaemia symptoms |
| FBC | Check for iron-deficiency anaemia (microcytic, low Hb, low ferritin) |
| TFTs, coagulation | Exclude thyroid disease, von Willebrand disease (especially in adolescents) |
| Pelvic USS | Structural causes: fibroids, polyps, adenomyosis, endometrial pathology |
Causes of HMB — PALM-COEIN Classification
Structural (PALM)
- Polyp — endometrial or cervical
- Adenomyosis — endometrial glands in myometrium; bulky tender uterus
- Leiomyoma (Fibroids) — most common benign uterine tumour; submucosal fibroids cause worst HMB
- Malignancy & Hyperplasia — must exclude
Non-structural (COEIN)
- Coagulopathy — von Willebrand disease, thrombocytopenia, anticoagulants
- Ovulatory dysfunction — PCOS, thyroid disease, hyperprolactinaemia
- Endometrial — primary endometrial disorder
- Iatrogenic — Cu-IUD, anticoagulants
- Not classified
Management Ladder
| Treatment | Mechanism | Notes |
|---|---|---|
| Tranexamic acid | Antifibrinolytic — inhibits plasminogen activation | 1g TDS during menstruation; reduces blood loss ~50%; non-hormonal option |
| Mefenamic acid (NSAID) | PGE2 inhibition → reduces endometrial vasodilation | 500mg TDS during period; also treats dysmenorrhoea; combine with tranexamic acid |
| Combined OCP | Anovulation; decidualisation of endometrium | Reduces blood loss 40–50%; regulates cycle; also treats dysmenorrhoea |
| LNG-IUS (Mirena) | Progestin → endometrial atrophy | Reduces blood loss 90%; NICE first-line hormonal Rx; 5-year device; also contraception |
| Oral progestogens | Endometrial suppression | Norethisterone 5mg TDS days 5–26; short-term option |
| GnRH analogues | Medical menopause → endometrial atrophy | Pre-operative shrinkage (fibroids), max 6 months without add-back HRT |
| Endometrial ablation | Destroys endometrium | Suitable if no desire for future fertility; 80% amenorrhoea/oligomenorrhoea |
| Hysterectomy | Definitive cure | Laparoscopic/abdominal/vaginal; TAH or TLH; last resort |
Dysmenorrhoea
Primary vs Secondary Dysmenorrhoea
Primary Dysmenorrhoea
No identifiable pelvic pathology. Caused by excessive prostaglandin E2 and F2α production from secretory endometrium → uterine hypercontractility, ischaemia, pain. Onset within 1–2 years of menarche; cramping pain radiating to lower back/thighs; begins hours before/at start of period.
Treatment
- NSAIDs — first-line: ibuprofen 400mg TDS, mefenamic acid; start before pain onset
- COCP — suppresses ovulation; relieves 90% of primary dysmenorrhoea
- Heat — topical heat as effective as ibuprofen in trials
- LNG-IUS — for women wanting contraception + dysmenorrhoea relief
Secondary Dysmenorrhoea
Underlying pelvic pathology. Causes: endometriosis (most common), adenomyosis, fibroids, pelvic inflammatory disease, IUD. Pain begins 1–2 weeks before period, worse throughout; may persist after period ends; dyspareunia common.
Investigation
- Pelvic USS — adenomyosis, fibroids, ovarian endometrioma ("chocolate cyst")
- Laparoscopy — gold standard for endometriosis diagnosis
- CA-125 — elevated in endometriosis (not specific)
Intermenstrual & Post-Coital Bleeding
Abnormal Uterine Bleeding — Investigate
| Type | Definition | Key Investigations | Pathology to Exclude |
|---|---|---|---|
| IMB (intermenstrual) | Bleeding between periods | STI swabs (chlamydia), USS, smear, colposcopy if indicated | Cervical ectropion, polyp, cervical cancer, chlamydia |
| PCB (post-coital) | Bleeding after sexual intercourse | Speculum exam, smear, STI screen, colposcopy | Cervical cancer (red flag), ectropion, cervicitis, polyp |
| PMB (post-menopausal) | Bleeding >12 months after final period | Pelvic USS (endometrial thickness), endometrial biopsy (Pipelle) | Endometrial cancer (most important), polyp, atrophy |
Red Flag: Post-menopausal bleeding
Treat as endometrial cancer until proven otherwise. Endometrial thickness >4mm on USS in post-menopausal woman requires biopsy. 10% of PMB in post-menopausal women is due to endometrial cancer.
GCC Cultural Context
Menstrual Health in the GCC
- Cultural and religious taboos around menstruation may delay help-seeking; women may normalise heavy or painful periods as "just part of life"
- Limited menstrual health education in schools in several GCC countries; awareness campaigns improving with Vision 2030 initiatives
- Fasting during Ramadan whilst managing heavy menstrual bleeding — iron deficiency risk; nursing advice required
- Menstrual irregularity often first presentation of PCOS — high prevalence in GCC (see Tab 3)
- Post-coital bleeding may be under-reported due to cultural sensitivity around sexual history disclosure
Interactive Clinical Tool
Menstrual Symptom Tracker & Assessment Tool
Enter the patient's menstrual history to receive a clinical assessment summary. For educational use only — not a substitute for clinical judgement.
Probable Condition
—
Urgency of Medical Review
—
Recommended Investigations
Lifestyle & Self-Care Advice
Cervical Screening
Cervical Smear — HPV Primary Screening
| Programme Element | Detail |
|---|---|
| Screening method | Liquid-based cytology (LBC) — cells suspended in preservative fluid; higher quality than conventional smear |
| Primary test (UK/most guidelines) | HPV primary screening: test for high-risk HPV first; cytology only if HPV positive |
| UK screening intervals | Age 25–49: every 3 years; Age 50–64: every 5 years |
| Routine recall | HPV negative → routine recall; HPV positive + normal cytology → repeat 12 months |
| Refer to colposcopy | HPV positive + abnormal cytology (ASCUS/LSIL/HSIL); or HPV positive at 12/24-month repeat |
CIN Grading & Management
| Grade | Histology | Management |
|---|---|---|
| CIN 1 | Low-grade; mild dysplasia; affects lower 1/3 of epithelium | Often regresses spontaneously; colposcopy surveillance; treatment if persists >2 years |
| CIN 2 | Moderate dysplasia; lower 2/3 of epithelium | Treatment recommended (LLETZ); may observe in young women (under 25) who may regress |
| CIN 3 | High-grade; severe dysplasia; full thickness (carcinoma in situ) | LLETZ (Large Loop Excision of Transformation Zone) — definitive treatment; follow-up smear at 6 months |
LLETZ Procedure — Nursing Points
Local anaesthetic; performed in colposcopy clinic; warn patient of watery/bloody discharge for 2–4 weeks; avoid intercourse/tampons for 4 weeks; risk of preterm birth in future pregnancies (especially with repeated LLETZ); test of cure at 6 months.
HPV Vaccination
Gardasil 9 — 9-Valent HPV Vaccine
- Covers: HPV types 6, 11 (genital warts) + 16, 18, 31, 33, 45, 52, 58 (oncogenic)
- HPV 16 & 18 cause ~70% of cervical cancers
- Target age: 9–14 years (2-dose schedule); 15+ years (3-dose schedule)
- Gender-neutral: Now recommended for boys and girls in most programmes
- School-based delivery in UK and expanding GCC programmes
GCC HPV Vaccination Status
Saudi Arabia, UAE, Qatar have national HPV vaccination programmes. Coverage improving with Vision 2030 health reforms. Cultural acceptance improving through school health nurses. Cervical cancer incidence low in GCC (lower HPV exposure due to Islamic marriage practices) but vaccination still critical for population protection.
Cervical Cancer
Cervical Carcinoma — Clinical Overview
Histological Types
- Squamous cell carcinoma — 70–80%; arises from transformation zone; HPV-driven
- Adenocarcinoma — 20%; arises from endocervical glandular cells; increasing incidence; HPV 18 associated; harder to detect on smear
Symptoms
- Post-coital bleeding (red flag)
- Intermenstrual bleeding
- Post-menopausal bleeding
- Watery/offensive vaginal discharge
- Pelvic pain, haematuria, rectal bleeding (advanced)
FIGO Staging
| Stage | Description | Treatment |
|---|---|---|
| I | Confined to cervix | Radical hysterectomy ± SLNB or chemoradiation |
| II | Beyond cervix, not pelvic wall/lower 1/3 vagina | Chemoradiation (cisplatin + RT) |
| III | Pelvic wall / lower vagina / hydronephrosis | Chemoradiation |
| IV | Bladder/rectum (IVA) or distant mets (IVB) | Palliative chemoradiation/systemic |
Endometrial Cancer
Endometrial Carcinoma — Most Common Gynaecological Cancer (Developed World)
Key Principle
Post-menopausal bleeding = endometrial cancer until proven otherwise. Refer urgently. 90% of endometrial cancers present with PMB — this is an early warning sign; 75% present at Stage I (good prognosis).
Risk Factors
- Obesity (BMI >30) — most important modifiable risk
- Unopposed oestrogen (no progesterone)
- Nulliparity, late menopause, early menarche
- Tamoxifen use (endometrial stimulation)
- PCOS (anovulation → unopposed oestrogen)
- Type 2 diabetes, hypertension
- Lynch syndrome (MSI-H, MMR mutation)
Investigation & Management
- Pelvic USS: endometrial thickness >4mm (post-menopausal) → biopsy
- Pipelle endometrial biopsy (outpatient) — sensitivity ~80%
- Hysteroscopy + biopsy — gold standard
- MRI for surgical planning (myometrial invasion depth)
- Treatment: total hysterectomy + bilateral salpingo-oophorectomy ± pelvic lymph node dissection
- High-risk features: adjuvant radiotherapy ± chemotherapy
Ovarian Cancer
Ovarian Carcinoma — "Silent Killer"
Why Detected Late
No effective screening programme. Vague symptoms: bloating, early satiety, urinary frequency, pelvic pain. Most present Stage III/IV. 5-year survival overall ~40%; Stage I >90%.
| Feature | Detail |
|---|---|
| Histology | High-grade serous (most common, 70%); endometrioid; clear cell; mucinous; low-grade serous |
| Risk factors | BRCA1 (lifetime risk 44%), BRCA2 (17%), Lynch syndrome, nulliparity, HRT, endometriosis |
| Protective | COCP (reduces risk ~50% with 5+ years use), multiparity, breastfeeding, tubal ligation, salpingectomy |
| Investigations | CA-125 (elevated in 80% epithelial ovarian cancers; also elevated in endometriosis/PID/fibroid); pelvic USS; CT chest/abdomen/pelvis; Risk of Malignancy Index (RMI) |
| Staging | FIGO I (confined to ovary) → II (pelvis) → III (peritoneum/lymph nodes) → IV (distant mets) |
| Treatment | Cytoreductive surgery (debulking) + carboplatin + paclitaxel chemotherapy. PARP inhibitors (olaparib/niraparib) as maintenance in BRCA1/2 mutation or HRD-positive disease |
GCC Gynaecological Cancer Context
GCC-Specific Considerations
- Lower cervical cancer incidence in GCC vs Western populations — attributed to lower HPV prevalence due to cultural/religious practices (monogamy, later sexual debut)
- Late presentation of all gynaecological cancers due to cultural reluctance to undergo pelvic examination, delayed healthcare-seeking, fear/stigma
- Limited historical cervical screening — several GCC states had no organised cervical screening programme until recently; improving with MOH reforms
- High endometrial cancer risk in GCC due to obesity epidemic, metabolic syndrome, PCOS, low parity in some demographics
- Female healthcare providers preferred by many GCC women — health systems must accommodate this preference
- Nursing role: health education around PMB, smear tests, cancer warning signs; liaison with female gynaecologists; culturally sensitive communication
PCOS Diagnosis
Rotterdam Criteria (2003) — 2 of 3 Required
1. Polycystic Ovaries on USS
≥20 follicles per ovary (2–9mm diameter) OR ovarian volume >10 mL on transvaginal USS. "String of pearls" appearance.
2. Oligo/Anovulation
Irregular or absent periods: cycles >35 days or <8 cycles/year. Amenorrhoea = absent periods for >3 months.
3. Clinical or Biochemical Hyperandrogenism
Clinical: acne, hirsutism (modified Ferriman-Gallwey score >4), androgenic alopecia. Biochemical: elevated free testosterone, DHEAS, SHBG low.
Exclusion Criteria — Must Rule Out Before Diagnosing PCOS
Congenital adrenal hyperplasia (17-OHP), Cushing's syndrome (24h urinary cortisol), thyroid dysfunction (TFTs), hyperprolactinaemia (prolactin), androgen-secreting tumour (rapid virilisation).
Epidemiology: Affects 10–15% of women of reproductive age; most common endocrine disorder in women. High prevalence in GCC and South Asian populations.
Metabolic Consequences
Long-term Metabolic Risks
| Complication | Relative Risk | Mechanism |
|---|---|---|
| Type 2 Diabetes Mellitus | 7× increased | Insulin resistance → hyperinsulinaemia → stimulates ovarian androgen production (vicious cycle) |
| Impaired Glucose Tolerance | Significantly elevated | Same as above; 30–40% of PCOS women have IGT by age 40 |
| Metabolic Syndrome | 2–3× increased | Central obesity, dyslipidaemia (↑TG, ↓HDL), hypertension, insulin resistance |
| Cardiovascular Disease | Elevated (long-term) | Dyslipidaemia, hypertension, DM, endothelial dysfunction |
| NAFLD/NASH | Elevated | Insulin resistance, central adiposity |
| Obstructive Sleep Apnoea | 5–10× increased | Obesity, androgen effects on upper airway |
| Endometrial Cancer | 3× increased | Anovulation → unopposed oestrogen stimulation → endometrial hyperplasia → malignancy |
Nursing Action: Endometrial Protection
Women with PCOS who are anovulatory and not on hormonal therapy must be counselled regarding endometrial cancer risk. Minimum 4 withdrawal bleeds per year required to protect endometrium. Prescribe norethisterone or combined pill if needed. Annual review recommended.
PCOS Management
Evidence-Based Treatment Approach
| Intervention | Evidence / Mechanism | Clinical Use |
|---|---|---|
| Lifestyle modification | Weight loss 5–10% restores ovulation in 55–80% of overweight women; reduces insulin resistance, testosterone, improves cycle regularity | First-line for all overweight/obese PCOS women; low GI diet + moderate aerobic exercise 150 min/week |
| Combined OCP | Suppresses LH → reduces ovarian androgen production; oestrogen increases SHBG → reduces free testosterone | Cycle regulation + hirsutism/acne management; Dianette (co-cyprindiol) for severe androgenic symptoms |
| Metformin | Insulin sensitiser; reduces hepatic gluconeogenesis; lowers insulin → reduces ovarian androgen; may restore ovulation | Irregular periods, T2DM prevention, adjunct to ovulation induction; 500mg OD increasing to 1500–2000mg daily; GI side effects common |
| Letrozole (aromatase inhibitor) | Reduces oestrogen → FSH rises → follicle development; better live birth rates than clomifene in overweight women | First-line ovulation induction (NICE 2023 guidance); 2.5–7.5mg days 2–6 of cycle |
| Clomifene citrate | Selective oestrogen receptor modulator → blocks negative feedback → FSH rise → ovulation | Ovulation induction; max 6 cycles; risk of multiple pregnancy (10%); USS monitoring required |
| Anti-androgens (spironolactone) | Aldosterone antagonist with anti-androgenic properties; blocks androgen receptors + inhibits androgen synthesis | Hirsutism/acne not responding to COCP; 100–200mg daily; contraception required (feminises male fetus) |
| Cyproterone acetate | Progestin with potent anti-androgenic activity | Severe hirsutism; component of Dianette (with ethinylestradiol); risk of VTE and hepatotoxicity |
| IVF | Bypasses need for ovulation induction | After failed ovulation induction; risk of OHSS in PCOS (see Tab 4) |
Psychological Impact
Mental Health & Quality of Life
- 2–3× increased rates of anxiety and depression in PCOS vs general population
- Body image concerns: weight, hirsutism, acne, androgenic alopecia
- Fertility concerns may cause significant psychological distress
- Eating disorders more prevalent
- Screen all PCOS patients with PHQ-9 (depression) and GAD-7 (anxiety)
- Refer to clinical psychology / CBT as appropriate; peer support groups
GCC Context
High social pressure to conceive in GCC societies makes PCOS-related subfertility particularly distressing. Hirsutism carries significant cultural stigma. Women may seek cosmetic treatments (laser hair removal, electrolysis) without addressing underlying PCOS. Nursing education should address the metabolic-reproductive connection holistically.
Infertility Assessment
Initial Fertility Workup
Female Assessment
| Test | What it assesses |
|---|---|
| Cycle regularity | Ovulatory status; regular cycles = presumed ovulation |
| Mid-luteal progesterone (Day 21) | Confirms ovulation (progesterone >30 nmol/L) |
| AMH (anti-Müllerian hormone) | Ovarian reserve; declines with age; useful for IVF planning |
| AFC (antral follicle count) | Transvaginal USS; counts resting follicles 2–10mm; correlates with ovarian reserve |
| Day 2–5 FSH, LH, oestradiol | High FSH indicates poor ovarian reserve / premature ovarian insufficiency |
| HyCoSy or HSG | Tubal patency; contrast USS (HyCoSy) or X-ray (HSG) |
| Laparoscopy ± dye test | Gold standard for tubal factor; diagnoses endometriosis, pelvic adhesions |
| TFTs, prolactin | Thyroid disease and hyperprolactinaemia cause anovulation |
Male Assessment
Semen Analysis (WHO 2021 Reference Values)
Volume ≥1.4 mL; concentration ≥16 million/mL; total motility ≥42%; progressive motility ≥30%; normal morphology ≥4% (Kruger strict criteria). Male factor identified in 40–50% of infertile couples.
- Azoospermia: no sperm — obstructive vs non-obstructive
- Oligospermia: low count; lifestyle (obesity/heat/smoking/steroids)
- Asthenospermia: poor motility
- Teratospermia: abnormal morphology
Unexplained infertility: 25–30% of couples; all investigations normal; may respond to empirical treatment or IVF
Assisted Reproductive Technology (ART)
IVF Process — Step by Step
| Technique | Indication | Details |
|---|---|---|
| IUI (Intrauterine Insemination) | Mild male factor, unexplained infertility, donor sperm | Washed sperm inserted into uterus around time of ovulation; success rate ~10–15% per cycle |
| IVF | Tubal factor, unexplained, endometriosis, ovulatory dysfunction | Eggs collected from stimulated ovaries, fertilised in lab, embryo transferred to uterus; ~25–35% live birth rate per cycle (age-dependent) |
| ICSI | Severe male factor (poor morphology/motility/count), failed fertilisation with IVF | Single sperm injected directly into oocyte; same live birth rate as IVF for non-male factor |
| PGT-A (Preimplantation Genetic Testing) | Recurrent miscarriage, advanced maternal age, chromosomal carriers | Biopsy of blastocyst to test for aneuploidies before transfer |
| Embryo Cryopreservation | Surplus embryos, risk of OHSS | Vitrification; frozen embryo transfer (FET) cycles available |
Ovarian Hyperstimulation Syndrome (OHSS)
OHSS — Classification & Management
| Severity | Features | Management |
|---|---|---|
| Mild | Bloating, abdominal discomfort, mild nausea, ovaries 8–12cm on USS | Outpatient; analgesia (paracetamol/codeine); adequate hydration; avoid intercourse; daily monitoring if worsening |
| Moderate | Moderate ascites on USS, nausea/vomiting, weight gain >3kg, haematocrit >41% | Close outpatient monitoring or consider admission; IV fluids if unable to maintain oral intake; LMWH (VTE prophylaxis); monitor FBC, electrolytes, renal function, weight daily |
| Severe | Tense ascites, oliguria (<300 mL/day), haematocrit >45%, hyponatraemia, WBC >25, ovaries >12cm | Admit; strict fluid balance; IV human albumin 20%; LMWH (TEDS/enoxaparin); cabergoline (reduces VEGF); consider paracentesis; restrict IV crystalloids (worsens third space losses) |
| Critical | Thromboembolic events (DVT/PE), ARDS, renal failure, cardiac tamponade | ICU admission; multidisciplinary team; cancel embryo transfer; no fresh transfer if severe/critical OHSS developing |
OHSS Prevention Strategies
Identify high-risk patients (PCOS, previous OHSS, AMH >3.4 ng/mL, AFC >24). Use GnRH antagonist protocol. Trigger with GnRH agonist instead of hCG (reduces OHSS). Freeze all embryos (avoid fresh transfer). Cabergoline from trigger day. Intravenous albumin at egg collection in high-risk patients.
Nursing Monitoring Parameters — OHSS
- Daily weight (weight gain >1kg/day = concern)
- Abdominal girth measurement
- Strict fluid balance — input/output chart; target urine output >30 mL/hour
- Haematocrit and FBC (haemoconcentration = haematocrit >45%)
- Electrolytes, urea, creatinine (renal impairment)
- Respiratory rate and oxygen saturation (pleural effusion/ARDS)
- LMWH administration and injection sites; TED stockings
GCC Fertility Context
Cultural, Religious & Regulatory Considerations
| Topic | GCC Context |
|---|---|
| IVF utilisation | GCC among highest IVF utilisation globally per capita; intense cultural and social pressure for childbearing; Islamic jurisprudence permits IVF within marriage |
| Donor gametes | Donor sperm and donor eggs: Sunni Islamic majority view considers third-party gametes impermissible (lineage principle — nasab). Shia Islam permits egg donation in some interpretations. Most GCC IVF centres use only couple's own gametes. |
| Surrogacy | Not permitted under Islamic law across GCC (considered akin to adoption of lineage). Legally prohibited in most GCC states. |
| Embryo disposition | Discarding surplus embryos is controversial; many couples request cryopreservation indefinitely. Centres must provide clear counselling. |
| Multiple pregnancy | High-order multiple pregnancies from aggressive stimulation carry significant risk; selective reduction is ethically contentious. Single embryo transfer policies expanding. |
| Nursing role | Cultural sensitivity paramount; involve family in counselling if requested; coordinate with Islamic scholars for patient queries; maintain confidentiality (infertility carries stigma) |
Menopause — Definitions
Natural Menopause & Perimenopause
Menopause
Cessation of menstruation for 12 consecutive months (retrospective diagnosis). Mean age: 51 years (UK); age 40–58 normal range. Caused by ovarian follicle depletion → oestrogen deficiency.
Perimenopause
Period leading up to menopause (months to years). Irregular cycles, vasomotor symptoms, psychological changes. FSH >30 IU/L on two occasions (if in doubt). Oestradiol fluctuates markedly.
Premature Ovarian Insufficiency (POI)
Menopause before age 40. Affects 1% of women. Causes: autoimmune, genetic (Turner syndrome, FMR1 premutation), iatrogenic (chemotherapy/radiotherapy/surgery). HRT until average age of menopause (51) for bone/cardiovascular protection.
Surgical Menopause
Bilateral oophorectomy at any age causes immediate menopause (abrupt oestrogen withdrawal — often more severe symptoms than natural menopause). Common in GCC due to hysterectomy with oophorectomy rates. HRT should be initiated promptly post-operatively.
Menopausal Symptoms
Symptom Assessment — Greene Climacteric Scale
| Domain | Symptoms | Assessment |
|---|---|---|
| Vasomotor | Hot flushes, night sweats, palpitations | Frequency (per day/night), severity (mild/moderate/severe), duration (seconds/minutes) |
| Psychological | Anxiety, depression, irritability, poor concentration, low libido, cognitive symptoms ("brain fog") | PHQ-9, GAD-7; distinguish from primary mental health disorder |
| Physical | Headaches, joint/muscle pain, fatigue, formication (crawling skin sensation) | Impact on daily function |
| Genitourinary | Vaginal dryness, dyspareunia, urinary frequency/urgency/recurrent UTI, incontinence | PISQ-12 for sexual symptoms; GSM assessment |
| Sleep | Insomnia (often secondary to night sweats); restless legs | Pittsburgh Sleep Quality Index; exclude sleep apnoea |
HRT — Hormone Replacement Therapy
HRT Principles & Formulations
Key Principle (NICE NG23, 2015 updated 2019)
HRT is the most effective treatment for menopausal symptoms. Benefits outweigh risks for most women under 60 or within 10 years of menopause. Individual risk assessment required. The timing hypothesis: HRT initiated early (within 10 years of menopause / <60 years) may have cardiovascular benefit; initiated late (>10 years after menopause) may increase cardiovascular risk.
Types of HRT
| Type | Indication |
|---|---|
| Oestrogen-only | Women who have had hysterectomy (no uterus — no progesterone needed) |
| Combined sequential | Intact uterus, perimenopausal; oestrogen daily + progestogen for 12–14 days/month → monthly withdrawal bleed |
| Combined continuous | Intact uterus, post-menopausal (>1 year since LMP); oestrogen + progestogen daily → aim for no bleed |
Routes of Administration
| Route | VTE Risk | Notes |
|---|---|---|
| Oral tablets | Higher (first-pass hepatic effect → clotting factors) | Convenient; easy dose adjustment |
| Transdermal patch | No increased VTE risk | Preferred for women with VTE risk factors, BMI >30, migraines |
| Gel / spray | No increased VTE risk | Flexible dosing; apply to thigh/arm |
| Vaginal (local) | Negligible systemic absorption | Treats GSM only; no progestogen needed; safe long-term |
HRT Risks & Benefits Summary
| Outcome | Effect | Notes |
|---|---|---|
| Vasomotor symptoms | Major benefit | 90% reduction in hot flushes/night sweats |
| Bone density / osteoporosis | Protective | Reduces hip fracture risk ~25%; protection maintained during use |
| Cardiovascular disease | Neutral / possible benefit if early | Timing hypothesis; transdermal preferred |
| Breast cancer (combined HRT) | Small increased risk | ~1 extra case per 1,000 women after 5 years combined HRT; less than risk from drinking 1 unit alcohol/day or obesity |
| Breast cancer (oestrogen-only) | No/minimal increase | Some studies show slight reduction; reassuring for hysterectomy patients |
| VTE (oral oestrogen) | 2× increased risk | Absolute risk small; use transdermal to avoid |
| Endometrial cancer | Risk with oestrogen-only (intact uterus) | Must add progestogen to protect endometrium if uterus present |
| Quality of life / mood | Benefit | Sleep, cognition, energy, mood, sexual function |
Non-Hormonal & GSM Management
Non-Hormonal Vasomotor Treatments & GSM
Non-Hormonal Vasomotor Options
| Drug | Mechanism | Notes |
|---|---|---|
| Venlafaxine (SNRI) | Norepinephrine/serotonin reuptake inhibition modulates thermoregulation | 37.5–75mg; 50–60% reduction in flushes; for women where HRT contraindicated (e.g. breast cancer) |
| Gabapentin | GABA analogue; central thermoregulatory modulation | 300mg nocte → TDS; drowsiness; useful if sleep disturbance dominant |
| Clonidine | Alpha-2 agonist; reduces vasomotor instability | 50–75 mcg BD; modest efficacy; side effects (dry mouth, drowsiness) |
| Fezolinetant | Neurokinin 3 receptor antagonist (KNDy pathway in hypothalamus) | 45mg OD; NICE approved 2024; non-hormonal; significant reduction in flushes |
Genitourinary Syndrome of Menopause (GSM)
Formerly "vulvovaginal atrophy." Encompasses: vaginal dryness, irritation, burning, dyspareunia, urinary urgency/frequency, recurrent UTI, reduced lubrication. Affects 50–70% of post-menopausal women but under-reported.
Local Oestrogen Treatments (GSM)
- Vaginal cream (conjugated oestrogens): apply 2–3x/week
- Vaginal pessaries (estriol/estradiol): 1–2x/week maintenance
- Vaginal ring (estradiol): replaced every 90 days
- Intravaginal DHEA (prasterone): converts locally to oestrogen/testosterone
- All have negligible systemic absorption; safe in breast cancer survivors (RCOG); no added progestogen needed
GCC Menopause Context
GCC-Specific Considerations
- Surgical menopause prevalence: high rates of hysterectomy (often with bilateral oophorectomy) in GCC countries; sudden onset menopause common; oestrogen-only HRT appropriate post-hysterectomy
- Vitamin D deficiency: endemic in GCC (despite high sunlight — cultural dress, indoor lifestyle); significantly worsens menopausal bone loss; supplement all post-menopausal women with Vitamin D3 800–2000 IU/day + calcium if dietary intake low
- Stigma around discussing menopause: "change of life" may not be discussed openly; women may present with vague symptoms; nurses should ask sensitively and directly
- Cardiovascular risk: high metabolic syndrome prevalence in GCC amplifies post-menopausal cardiovascular risk; HRT timing discussions especially important
- Bone health: osteoporosis under-diagnosed; DEXA scanning access improving; bisphosphonates (alendronate/risedronate) as alternative to HRT for bone protection
GCC Women's Health — System Overview
Key Challenges & Reforms
| Challenge | Detail | Progress |
|---|---|---|
| Delayed gynaecological help-seeking | Cultural barriers, stigma around pelvic examination, preference for female doctors not always available | Increasing female gynaecologists/nurses; telehealth consults; patient education campaigns |
| Cervical screening uptake | Some countries lacked organised national programmes; low uptake due to cultural attitudes | Saudi MOH expanded cervical screening; UAE National Screening Programme; awareness campaigns |
| PCOS epidemic | Rising prevalence linked to obesity epidemic, sedentary lifestyle, consanguinity | Increased awareness; lifestyle clinics; multidisciplinary PCOS teams at major hospitals |
| High IVF demand | Cultural imperative for childbearing; high number of ART cycles per capita | Regulated IVF clinics; DHA/MOH licensing; OHSS protocols improving |
| Vitamin D deficiency | Near-universal deficiency in GCC women; impacts bone health, immunity, pregnancy outcomes | National supplementation programmes; routine testing in antenatal care |
Saudi Vision 2030 — Women's Health Initiatives
Preventive health screening programmes (cervical, breast, colorectal cancer screening). National women's health strategy. Expansion of women's health clinics. Increased female workforce in healthcare. HPV vaccination programme in schools. Metabolic syndrome prevention campaigns.
Licensing Exam Focus Areas
DHA / DOH / SCFHS / HAAD Women's Health Topics
High-Yield Exam Topics
- Rotterdam criteria for PCOS diagnosis
- Post-menopausal bleeding management pathway
- LNG-IUS as NICE first-line for HMB
- OHSS classification and management (LMWH, albumin)
- CIN grading and LLETZ follow-up
- HRT routes and VTE risk (oral vs transdermal)
- Primary vs secondary dysmenorrhoea
- HPV primary screening process
- Ovarian cancer symptoms and CA-125
- Endometrial cancer risk factors (PCOS, obesity, tamoxifen)
Key Numbers to Remember
| Value | What it represents |
|---|---|
| >80 mL | Menorrhagia threshold |
| >100 | PBAC score indicating HMB |
| 28 ± 7 days | Normal menstrual cycle |
| 51 years | Mean age of natural menopause |
| >4mm | Endometrial thickness requiring biopsy (PMB) |
| 10% | Approximate cancer rate in PMB |
| 5–10% | Weight loss to restore ovulation in PCOS |
| 7× | Increased T2DM risk in PCOS |
| 90% | Blood loss reduction with LNG-IUS |
| 9–14 years | HPV vaccination target age |
MCQ Practice — 10 Questions